Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Primary biliary cholangitis (PBC) is a chronic, inflammatory, cholestatic liver disease predominantly affecting women.
• Disease progression varies, potentially leading to biliary cirrhosis.
• Current management includes ursodeoxycholic acid, with newer therapies like obeticholic acid and fibrates for non-responders.

Purpose of the Study:

• To review advancements in understanding PBC disease biology.
• To highlight current and emerging therapeutic strategies.
• To discuss challenges in immunotherapy and symptom management.

Main Methods:

• Review of current literature on PBC pathogenesis and treatment.
• Focus on nuclear receptor pathway modulation (FXR, PPARs).
• Examination of novel approaches for symptom control, such as ASBT inhibitors.

Main Results:

• Nuclear receptor agonists are redefining PBC therapy by enhancing bile excretion, reducing inflammation, and mitigating fibrosis.
• Personalized risk stratification is improving patient care.
• Targeting bile acid transport offers a rational approach for symptom management, notably pruritus.

Conclusions:

• Therapeutic strategies for PBC are evolving, with significant progress in targeting molecular pathways.
• Further research is needed to address challenges in PBC immunotherapy.
• Symptom management, particularly pruritus, remains a key clinical goal with developing targeted therapies.